Early access
Sign in
Taking people in GermanyPhase 1

Tests CLN-978 in adults with moderate to severe Sjogren's disease

Tests the drug CLN-978 in adults with active, moderate to severe Sjogren's disease.

Key facts

Who runs it
Cullinan Therapeutics Inc.
Where
Erlangen and Hanover, GermanySee the 2 sitesAlso in 3 other countries, 11 sites
Registry title
A Phase 1b, Open-Label Study of CLN-978 for the Treatment of Active, Moderate to Severe Sjogren’s Disease
Status
Recruiting
Phase
Phase 1
People taking part
40 people, planned
Started
5 Aug 2025
Expected to end
31 Dec 2028
Type of study
Interventional
Record updated
6 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with active, moderate to severe Sjogren's disease. Everyone in the trial receives the study drug CLN-978.

Age
18 years and older
Sex
All sexes can join
Disease stage
Active, moderate to severe Sjogren's disease

Where in Germany

Also in 3 other countries, 11 sites

  • Universitaetsklinikum Erlangen AöRErlangen, GermanyTaking people
  • Medizinische Hochschule HannoverHanover, GermanyTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Tests CLN-978 in adults with moderate to severe Sjogren's diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
6 May 2026